Re-treatment of Participants With Paget's Disease Using Zoledronic Acid
Status:
Completed
Trial end date:
2011-03-14
Target enrollment:
Participant gender:
Summary
The purpose of this study was to demonstrate that participants with Paget's disease of the
bone who had responded to zoledronic acid treatment as participants in the core registration
studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully
treated with a 5 milligram (mg) infusion of zoledronic acid.